Clenbuterol [β2-Agonists]

[memfaction]

I've read quite a lot articles about clenbuterol and since I've never used it before, I'm most concerned about it's side effects. There are plenty of short-term side effects, but I couldn't find any information on long term, permanent side effects. To be more precise, how much damage would I make to heart if I would run it for 2x2 weeks? I know that I should take 5000 mg of Taurine and 1000 mg of Potassium with it, but still: should I be worried?

 

[TheAnabolicStore]

Unless you’re competing, it’s really not worth the risk. Just be stronger with your diet.

I am aware of a few competitors that prefer to use stuff like yohimbine over clenbuterol. I’m not saying yohimbine is 100% safe, but it’s a better bet in my book.

Careful with recommending yohimbe, it comes with its own very serious side effects even at surprisingly low dosages of 40mg.

 

[Michael Scally MD]

[OA] Can β2-agonists have an ergogenic effect on strength, sprint or power performance?

Objectives: We aimed to examine the effect of β2-agonists on anaerobic performance in healthy non-asthmatic subjects.

Design: Systematic review and meta-analysis.

Eligibility criteria: We searched four databases (PubMed, Embase, SPORTDiscus and Web of Science) for randomised controlled trials, published until December 2019, examining the effect of β2-agonists on maximal physical performance lasting 1 min or shorter. Data are presented as standardised difference in mean (SDM) with 95% confidence intervals (95% CI).

Results: 34 studies were included in the present meta-analysis. The studies include 44 different randomised and placebo-controlled comparisons with β2-agonists comprising 323 participants in crossover trials, and 149 participants in parallel trials.

In the overall analyses, β2-agonists improved anaerobic performance by 5% (SDM 0.29, 95% CI 0.16 to 0.42), but the effect was related to dose and administration route. In a stratified analysis, the SDM was 0.14 (95% CI 0.00 to 0.28) for approved β2-agonists and 0.46 (95% CI 0.24 to 0.68) for prohibited β2-agonists, respectively.

Furthermore, SDM was 0.16 (95% CI 0.02 to 0.30) for inhaled administration and 0.51 (95% CI 0.25 to 0.77) for oral administration, respectively, and 0.20 (95% CI 0.07 to 0.33) for acute treatment and 0.50 (95% CI 0.20 to 0.80) for treatment for multiple weeks.

Analyses stratified for the type of performance showed that strength (0.35, 95% CI 0.15 to 0.55) and sprint (0.17, 95% CI 0.06 to 0.29) performance were improved by β2-agonists.

Conclusion/implication: Our study shows that non-asthmatic subjects can improve sprint and strength performance by using β2-agonists. It is uncertain, however, whether World Anti-Doping Agency (WADA)-approved doses of β2-agonists improve performance. Our results support that the use of β2-agonists should be controlled and restricted to athletes with documented asthma.

Riiser A, Stensrud T, Stang J, Andersen LB. Can β2-agonists have an ergogenic effect on strength, sprint or power performance? Systematic review and meta-analysis of RCTs [published online ahead of print, 2020 Aug 3]. Br J Sports Med. 2020;bjsports-2019-100708. doi:10.1136/bjsports-2019-100708 Can β2-agonists have an ergogenic effect on strength, sprint or power performance? Systematic review and meta-analysis of RCTs

 

[Michael Scally MD]

[OA] Clenbuterol-Induced Myocarditis: A Case Report

Objective: We present a case of a 22-year-old bodybuilder diagnosed with myocarditis secondary to clenbuterol use.

Results: The patient was primarily managed conservatively by the discontinuation of clenbuterol and the temporary use of dual anti-platelets, beta-blockers and nitrates.

Conclusion: Clenbuterol is a long-acting beta-2 agonist primarily used in veterinary medicine. In recent years, it has been illegally marketed as a weight loss supplement because of its anabolic properties and is popular among fitness enthusiasts. It is our aim to use this case to underscore the adverse effects of this drug with hopes that tighter regulations will be instituted to stem its illegal distribution.

Learning points: Clenbuterol is primarily a veterinary drug with bronchodilator and tocolytic properties. It is illegally used as a performance enhancer by athletes and bodybuilders because of its anabolic properties. Clenbuterol misuse can result in myocardial injury.

Moriarty N, Attar N. Clenbuterol-Induced Myocarditis: A Case Report. Eur J Case Rep Intern Med. 2020;7(9):001662. Published 2020 Jun 24. doi:10.12890/2020_001662 https://www.ejcrim.com/index.php/EJCRIM/article/view/1662/2215

 

[Michael Scally MD]

Can β2-agonists have an ergogenic effect on strength, sprint or power performance?

Objectives We aimed to examine the effect of β2-agonists on anaerobic performance in healthy non-asthmatic subjects.

Design Systematic review and meta-analysis.

Eligibility criteria We searched four databases (PubMed, Embase, SPORTDiscus and Web of Science) for randomised controlled trials, published until December 2019, examining the effect of β2-agonists on maximal physical performance lasting 1 min or shorter. Data are presented as standardised difference in mean (SDM) with 95% confidence intervals (95% CI).

Results 34 studies were included in the present meta-analysis. The studies include 44 different randomised and placebo-controlled comparisons with β2-agonists comprising 323 participants in crossover trials, and 149 participants in parallel trials.

In the overall analyses, β2-agonists improved anaerobic performance by 5% (SDM 0.29, 95% CI 0.16 to 0.42), but the effect was related to dose and administration route. In a stratified analysis, the SDM was 0.14 (95% CI 0.00 to 0.28) for approved β2-agonists and 0.46 (95% CI 0.24 to 0.68) for prohibited β2-agonists, respectively.

Furthermore, SDM was 0.16 (95% CI 0.02 to 0.30) for inhaled administration and 0.51 (95% CI 0.25 to 0.77) for oral administration, respectively, and 0.20 (95% CI 0.07 to 0.33) for acute treatment and 0.50 (95% CI 0.20 to 0.80) for treatment for multiple weeks. Analyses stratified for the type of performance showed that strength (0.35, 95% CI 0.15 to 0.55) and sprint (0.17, 95% CI 0.06 to 0.29) performance were improved by β2-agonists.

Conclusion/implication Our study shows that non-asthmatic subjects can improve sprint and strength performance by using β2-agonists. It is uncertain, however, whether World Anti-Doping Agency (WADA)-approved doses of β2-agonists improve performance. Our results support that the use of β2-agonists should be controlled and restricted to athletes with documented asthma.

Riiser A, Stensrud T, Stang J, Andersen LB. Can β2-agonists have an ergogenic effect on strength, sprint or power performance? Systematic review and meta-analysis of RCTs. Br J Sports Med. 2020 Nov;54(22):1351-1359. doi: 10.1136/bjsports-2019-100708. Epub 2020 Aug 3. PMID: 32747344. Can β2-agonists have an ergogenic effect on strength, sprint or power performance? Systematic review and meta-analysis of RCTs | British Journal of Sports Medicine

 

[asmo1992]

Hmm if I would ask, why do U all prefer clen than EC. I love EC and feeling good and I started to "podumali" and ask myself why? is Clen dat stronger to risk this bad feelingz (shaking hands, HR thru da roof etc)?